Tag Archives: Ed Arce

Analysts Are Bullish on Top Healthcare Stocks: Galectin Therapeutics (GALT), Stoke Therapeutics (STOK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galectin Therapeutics (GALT – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. Galectin Therapeutics (GALT) In a report

Analysts’ Top Healthcare Picks: Akero Therapeutics (AKRO), Protagonist Therapeutics (PTGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akero Therapeutics (AKRO – Research Report), Protagonist Therapeutics (PTGX – Research Report) and RAPT Therapeutics (RAPT – Research Report) with bullish sentiments.

H.C. Wainwright Keeps a Buy Rating on Arbutus Biopharma (ABUS)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) on January 26 and set a price target of $10.00. The company’s shares closed last Tuesday at $3.60. According to TipRanks.com, Arce is a

Intercept Pharma (ICPT) Got Some Bad News

H.C. Wainwright analyst Ed Arce downgraded Intercept Pharma (ICPT – Research Report) to Sell yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $28.12, close to its 52-week low of $23.78. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Paratek Pharmaceuticals (NASDAQ: PRTK), Biogen (NASDAQ: BIIB) and Eli Lilly & Co (NYSE: LLY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Paratek Pharmaceuticals (PRTK – Research Report), Biogen (BIIB – Research Report) and Eli Lilly & Co (LLY – Research Report). Paratek Pharmaceuticals (PRTK) H.C. Wainwright

H.C. Wainwright Reaffirms Their Hold Rating on Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today. The company’s shares closed last Monday at $1.81. According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.5% and